Cancer Moonshot℠ FY2023, FY2022, FY2021, FY2020, FY2019, FY2018, and FY2017 Funding Opportunities
Following the authorization of the 21st Century Cures Act, and the appropriation of $300 million in each fiscal year (FY) 2017 and FY 2018, NCI released the funding opportunity announcements (FOAs) listed below to high-priority research initiatives that align with the efforts of the Cancer Moonshot.
| BRP Recommendation | Title | Announcement Number |
|---|---|---|
|
Generation of Human Tumor Atlases |
Request for Information (RFI) on Challenges and Opportunities Associated with Multidimensional Tumor Atlases |
| BRP Recommendation | Title | Announcement Number |
|---|---|---|
| New Enabling Technologies | Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection In Vivo (R01 Clinical Trial Optional) | PAR-20-295 |
| Human Tumor Atlas Network | 3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed) | RFA-CA-21-037 |
| BRP Recommendation | Title | Announcement Number |
|---|---|---|
| Direct Patient Engagement Network | Patient Engagement and Cancer Genome Sequencing (PE-CGS): Research Centers (U2C Clinical Trial Optional) | RFA-CA-19-045 |
| National Cancer Data Ecosystem | Visualization Methods and Tools Development for Enhancing Cancer Moonshot Data (R33 Clinical Trial Not Allowed) | RFA-CA-20-044 |
| Human Tumor Atlas Network | 3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed) | RFA-CA-20-042 |
| Therapeutic Target Identification to Overcome Resistance | Revision Applications for Mechanisms of Cancer Drug Resistance (R01 Clinical Trial Not Allowed) | RFA-CA-19-049 |
| Pediatric Immunotherapy Network | Request for Information (RFI): Input for National Cancer Institute (NCI) Pediatric Immunotherapy Network | NOT-CA-21-086 |
| Adult Immunotherapy Network | Notice of Special Interest: Administrative Supplements for Cancer Moonshot awardees and Cancer Center Support Grants (CCSG) to Support Development of an "Immune Radiation Response Index (i-RRI)" for Immune Cells from Normal and Tumor Microenvironments | NOT-CA-21-083 |
| BRP Recommendation | Title | Announcement Number |
|---|---|---|
| Direct Patient Engagement Network | Patient Engagement and Cancer Genome Sequencing (PE-CGS): Coordinating Center (U24 Clinical Trial Not Allowed) | RFA-CA-19-046 |
| Drug Resistance Network | Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations with the NCI-supported Drug Resistance and Sensitivity Network (DRSN) | NOT-CA-20-014 |
| BRP Recommendation | Title | Announcement Number |
|---|---|---|
| New Enabling Technologies | Novel Technology Tools to Facilitate Research Using Next Generation Patient-derived Cancer Models (U01 Clinical Trial Not Allowed) | RFA-CA-19-055 |
| Prevention and Early Detection: Implementation Science | Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01) | RFA-CA-19-017 |
| Prevention and Early Detection: Implementation Science | Communication and Decision Making for Individuals with Inherited Cancer Syndromes (U01) | RFA-CA-19-001 |
| Prevention and Early Detection: Implementation Science | Implementation Science for Cancer Control: Developing Centers (P50 Clinical Trial Optional) | RFA-CA-19-005 |
| Prevention and Early Detection: Implementation Science | Implementation Science for Cancer Control: Advanced Centers (P50 Clinical Trial Optional) | RFA-CA-19-006 |
| Cancer Immunotherapy Translational Science Network | Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (UG3/UH3 Clinical Trials Not Allowed) | RFA-CA-19-012 |
| Cancer Immunotherapy Translational Science Network | Immuno-Oncology Translation Network (IOTN): Immuno-engineering to Improve Immunotherapy (i3) Centers (U54 Clinical Trial Not Allowed) | RFA-CA-19-013 |
| Cancer Immunotherapy Translational Science Network | Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (U01 Clinical Trial Not Allowed) | RFA-CA-19-014 |
| Cancer Immunotherapy Translational Science Network | Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy Research Projects (U01 Clinical Trial Not Allowed) | RFA-CA-19-015 |
| Prevention and Early Detection: Implementation Science | Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS, Second Wave) (UG3/UH3 Clinical Trial Required) | RFA-CA-19-018 |
| Therapeutic Target Identification to Overcome Resistance | Notice of Special Interest: Administrative Supplements to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN) | NOT-CA-19-032 |
| New Enabling Technologies | Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet) (Admin Supp Clinical Trial Not Allowed) | PA-19-174 |
| Cancer Immunotherapy Translational Science Network | Advancing Cancer Immunotherapy by Mitigating Immune-Related Adverse Events (irAE) (U01 Clinical Trial Not Allowed) | RFA-CA-19-044 |
| Cancer Immunotherapy Translational Science Network | Notice of Special Interest: Administrative Supplements for Activities to Promote Human Immune-Representing Oncology Models | NOT-CA-19-028 |
| New Enabling Cancer Technologies | Spatial Sequencing Technologies with Single Cell Resolution for Cancer Research | PHS 2020-1/Topic 403 |
| New Enabling Cancer Technologies | Subcellular Microscopy and -Omics in Cancer Cell Biology | PHS 2020-1/Topic 404 |
| New Enabling Cancer Technologies | Intra-Tumor Sensing Technologies for Tumor Pharmacotyping | PHS 2020-1/Topic 405 |
| Prevention and Early Detection | Software for Patient Navigation Through the Cancer Care Continuum | PHS 2020-1/Topic 406 |
| National Cancer Data Ecosystem | Cloud-Based Software for the Cancer Research Data Commons | PHS 2020-1/Topic 407 |
| Generation of Human Tumor Atlases | Tools and Technologies for Visualizing Multi-Scale Data | PHS 2020-1/Topic 408 |
| Network for Patient Engagement | Cancer Clinical Trials Recruitment and Retention Tools for Participant Engagement | PHS 2020-1/Topic 410 |
| Symptom Management Research | Software Enabling Data Integration from Wearable Sensors for Cancer Patients | PHS 2020-1/Topic 412 |
| Cancer Immunotherapy Translational Science Network | Pediatric Immunotherapy-Discovery and Development Network (PI-DDN) (U54) | RFA-CA-19-003 |
| Cancer Immunotherapy Translational Science Network | Pediatric Immunotherapy- Discovery and Development Network (PI-DDN) (U01) | RFA-CA-19-004 |
| Drivers of Childhood Cancers | Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54) | RFA-CA-19-016 |
| BRP Recommendation | Title | Announcement Number |
|---|---|---|
| Adult Immunotherapy Translational Science Network | Immuno-Oncology Translation Network (IOTN): CIDR (U24) | RFA-CA-17-048 |
| Adult Immunotherapy Translational Science Network | Immuno-Oncology Translation Network (IOTN): DMRC (U24) | RFA-CA-17-047 |
| Adult Immunotherapy Translational Science Network | Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention (U01) | RFA-CA-17-046 |
| Adult Immunotherapy Translational Science Network | Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics (R43/44) | PHS2018-1/Topic 372 |
| Adult Immunotherapy Translational Science Network | Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy (U01) | RFA-CA-17-045 |
| Pediatric Immunotherapy Translational Science Network | Pediatric Immunotherapy Discovery and Development Network (PI-DDN) (U01) | RFA-CA-17-051 |
| Pediatric Immunotherapy Translational Science Network | Pediatric Immunotherapy Discovery and Development Network (PI-DDN) (U54) | RFA-CA-17-050 |
| Drivers of Childhood Cancers | Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54) | RFA-CA-17-049 |
| Generation of Human Tumor Atlases | Human Tumor Atlas Network: Data Coordinating Center (U24) | RFA-CA-17-036 |
| Generation of Human Tumor Atlases | Pre-Cancer Atlas (PCA) Research Centers (U2C) | RFA-CA-17-035 |
| Generation of Human Tumor Atlases | Imaging-Based Tools for Longitudinal and Multi-Dimensional Mapping of the Tumor and its Microenvironment (R43/R44) | PHS2018-1/Topic 376 |
| Generation of Human Tumor Atlases | Human Tumor Atlas Research Centers (U2C) | RFA-CA-17-034 |
| Hereditary Cancers | Approaches to Identify & Care for Individuals w/ Inherited Cancer Syndromes (U01) | RFA-CA-17-041 |
| Prevention and Screening | ACCSIS: Coordinating Center (U24) | RFA-CA-17-039 |
| Prevention and Screening | ACCSIS (UG3/UH3) | RFA-CA-17-038 |
| Symptom Management Research | Analyzing & Interpreting Clinician & Patient Adverse Event Data to Understand Tolerability (U01) | RFA-CA-17-052 |
| Symptom Management Research | Coordinating Center for Research Centers for Improving Management of Symptoms (U24) | RFA-CA-17-043 |
| Symptom Management Research | Bridging the Guideline Implementation Gap: Clinical Decision-Support to Improve Cancer Symptom Management (R43/R44) | PHS2018-1/Topic 377 |
| Symptom Management Research | Software Enabling Data Integration from Wearable Sensors to Generate Novel Analytics for Cancer Patients (R43/R44) | PHS2018-1/Topic 379 |
| Symptom Management Research | Research Centers for Improving Management of Symptoms (UM1) | RFA-CA-17-042 |
| Therapeutic Target Identification to Overcome Resistance | Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24) | RFA-CA-17-044 |
| New Enabling Technologies | Minority Patient-Derived Xenograft (PDX) Development and Trial Centers (M-PDTCs) (U54) | RFA-CA-17-032 |
| New Enabling Technologies | Supplements to Support Collaborations with the PDXNet (Admin Supp) | PA-18-496 |
| New Enabling Technologies | Diagnostic Imaging for Cancer Immunotherapies (R43/R44) | PHS2018-1/Topic 375 |
| New Enabling Technologies | Tools and Technologies for Monitoring RNA Modifications (R43) | PHS2018-1/Topic 373 |
| New Enabling Technologies | Computer Aided Decision Support for Radiation Oncology (R43/R44) | PHS2018-1/Topic 380 |
| Drivers of Childhood Cancers | APRC on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp) | PA-17-138 |
| New Enabling Technologies | APTRC for Cancer Research (Admin Supp) | PA-17-143 |
| Prevention and Early Detection: Implementation Science | Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R01) | PAR-16-202 |
| Prevention and Early Detection: Implementation Science | Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R21) | PAR-16-201 |
| Prevention and Early Detection: Implementation Science | Dissemination and Implementation Research in Health (R21) | PAR-16-236 |
| Prevention and Early Detection: Implementation Science | Dissemination and Implementation Research in Health (R01) | PAR-16-238 |
| BRP Recommendation | Title | Announcement Number |
|---|---|---|
| Adult Immunotherapy Translational Science Network | Canine Immunotherapy Trials and Correlative Studies (U01) | RFA-CA-17-001 |
| Adult Immunotherapy Translational Science Network | Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24) | RFA-CA-17-002 |
| Adult Immunotherapy Translational Science Network | Consortium for PDAC Translational Studies on the Tumor Microenvironment (U01) | RFA-CA-17-015 |
| Adult Immunotherapy Translational Science Network | Resource Center for the Consortium for PDAC Translational Studies (U24) | RFA-CA-17-016 |
| Adult Immunotherapy Translational Science Network | Cancer Immune Monitoring and Analysis Centers (CIMACs) (U24) | RFA-CA-17-005 |
| Adult Immunotherapy Translational Science Network | Cancer Immunologic Data Common (CIDC) (U24) | RFA-CA-17-006 |
| Adult Immunotherapy Translational Science Network | Limited Competition: Cancer Immunotherapy Trials Network (CITN) (UM1) | RFA-CA-16-501 |
| Adult Immunotherapy Translational Science Network | APRC-irAEs Associated with Cancer Immunotherapy (Admin Supp) | PA-17-248 |
| New Enabling Technologies | PDX Development and Trial Centers (PDTCs) (U54) | RFA-CA-17-003 |
| New Enabling Technologies | PDX Data Commons and Coordinating Center (PDCCC) for the PDXNet (U24) | RFA-CA-17-004 |
| New Enabling Technologies | Integration and Validation of Emerging Technologies to Accelerate Cancer Research (R33) | RFA-CA-17-023 |
| Therapeutic Target Identification to Overcome Resistance | Mechanisms of Cancer Drug Resistance and Sensitivity (U54) | RFA-CA-17-009 |